[2-fluoro-3-[3-[6-(methoxymethyl)pyridin-3-yl]oxyazetidin-1-yl]phenyl]methyl N-carbamimidoylcarbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: [2-fluoro-3-[3-[6-(methoxymethyl)pyridin-3-yl]oxyazetidin-1-yl]phenyl]methyl N-carbamimidoylcarbamate
• 化学式: C₁₉H₂₂FN₅O₄
• 分子量: 403.4
• InChiKey: YKUQPALNRUVDHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• GUANIDINE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20150203480A1

  公开（公告）日：2015-07-23

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

  [问题]本发明提供了一种化合物，该化合物可用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 [解决手段]本发明人对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，并且可用于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，从而完成了本发明。此外，本发明涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，该药物组合物包括本发明的化合物或其盐以及一种赋形剂。
• US8716470B2
  申请人：——

  公开号：US8716470B2

  公开（公告）日：2014-05-06
• US9051283B2
  申请人：——

  公开号：US9051283B2

  公开（公告）日：2015-06-09
• US9556160B2
  申请人：——

  公开号：US9556160B2

  公开（公告）日：2017-01-31